MATTHEW STROMBERG: Open Payments
NPI 1922888429 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,153 in 213 payments from 15 companies in 2025. Trend: 2023 $250 · 2024 $3,360 · 2025 $4,153
Food & beverage: $4,153
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 36 | $721 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $606 |
| Alkermes, Inc. | 24 | $495 |
| ABBVIE INC. | 22 | $478 |
| Otsuka America Pharmaceutical, Inc. | 18 | $404 |
| Corium, LLC | 19 | $353 |
| Supernus Pharmaceuticals, Inc. | 21 | $273 |
| E.R. Squibb & Sons, L.L.C. | 15 | $183 |
| Collegium Pharmaceutical, Inc. | 8 | $146 |
| Neurocrine BioSciences, Inc. | 6 | $144 |
Products named: CAPLYTA, UZEDY, VRAYLAR, ARISTADA, Azstarys, REXULTI, Qelbree, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
